123 related articles for article (PubMed ID: 15131492)
1. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.
Gorman JM; Korotzer A; Su G
CNS Spectr; 2002 Apr; 7(4 Suppl 1):40-4. PubMed ID: 15131492
[TBL] [Abstract][Full Text] [Related]
2. Sertraline versus escitalopram in South Asians with moderate to severe major depressive disorder: (SOUTH-DEP) a double-blind, parallel, randomized controlled trial.
Raza S; Ahmed S; Islam R; Ahmed M; Ashraf S; Islam H; Kiyani H; Saqib M; Shah SAR; Mumtaz H
Ann Med Surg (Lond); 2023 Oct; 85(10):4851-4859. PubMed ID: 37811114
[TBL] [Abstract][Full Text] [Related]
3. A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults.
He S; Yu Y; Huang J; Yin J; Niu Y; Lu Y; Wu B; Fang M; Wang X; Tao Z; Li L; Li K; Li Y; Ding X; Shen Y; Li H
Ther Adv Psychopharmacol; 2023; 13():20451253231212342. PubMed ID: 38022835
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of escitalopram in the treatment of major depressive disorder.
Ali MK; Lam RW
Neuropsychiatr Dis Treat; 2011; 7():39-49. PubMed ID: 21430793
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of citalopram or escitalopram in patients with asthma and major depressive disorder.
Agarwal CD; Palka JM; Gajewski AJ; Khan DA; Brown ES
Ann Allergy Asthma Immunol; 2024 Mar; 132(3):374-382. PubMed ID: 37952772
[TBL] [Abstract][Full Text] [Related]
6. Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial.
Wang Y; Lu Z; Xun G
J Affect Disord; 2024 Jan; 344():159-168. PubMed ID: 37827257
[TBL] [Abstract][Full Text] [Related]
7. Transcutaneous Electrical Cranial-Auricular Acupoint Stimulation vs. Escitalopram for Patients With Mild-to-Moderate Depression (TECAS): Study Design for a Randomized Controlled, Non-inferiority Trial.
Yang S; Qin Z; Yang X; Chan MY; Zhang S; Rong P; Hou X; Jin G; Xu F; Liu Y; Zhang ZJ
Front Psychiatry; 2022; 13():829932. PubMed ID: 35619617
[TBL] [Abstract][Full Text] [Related]
8. Complementary use of tai chi chih augments escitalopram treatment of geriatric depression: a randomized controlled trial.
Lavretsky H; Alstein LL; Olmstead RE; Ercoli LM; Riparetti-Brown M; Cyr NS; Irwin MR
Am J Geriatr Psychiatry; 2011 Oct; 19(10):839-50. PubMed ID: 21358389
[TBL] [Abstract][Full Text] [Related]
9. Effect of solution focused group therapy on depressive symptoms and cognitive flexibility of depressive disorder patient.
Duan D; Wang W; Zhang J; Gu Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Sept 28; 48(9):1343-1349. PubMed ID: 38044645
[TBL] [Abstract][Full Text] [Related]
10. Early symptom improvement and other clinical predictors of response to repetitive transcranial magnetic stimulation for depression.
Winninge M; Cernvall M; Persson J; Bodén R
J Affect Disord; 2024 Jun; 361():383-389. PubMed ID: 38897300
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness, safety and adherence to therapy with Elicea Q-Tab in real clinical practice].
Oleichik IV; Shishkovskaia TI; Baranov PA
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(11. Vyp. 2):46-54. PubMed ID: 38127700
[TBL] [Abstract][Full Text] [Related]
12. Comparison of clinical efficacy of oxcarbazepine and lamotrigine combined with escitalopram, and impact on prognostic quality of life in treating patients with epilepsy and depressive disorder.
Zhang X; Zhao W
Exp Ther Med; 2020 Dec; 20(6):146. PubMed ID: 33093884
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of adding celecoxib to escitalopram for improving symptoms of major depressive disorder.
Nadi Sakhvidi M; Salami Z; Mosadegh M; Bidaki R; Fallahzadeh H; Salehabadi R; Arjmandi M
Int J Psychiatry Med; 2023 Nov; ():912174231210567. PubMed ID: 38116669
[TBL] [Abstract][Full Text] [Related]
14. Improvement of hedonic perception of odors as a marker of treatment response to escitalopram: olfactory changes through an open-label antidepressant trial.
Kazour F; Atanasova B; Desmidt T; Gissot V; Lefevre A; Camus V; Belzung C; El-Hage W
Braz J Psychiatry; 2023; 45(5):414-422. PubMed ID: 37718120
[TBL] [Abstract][Full Text] [Related]
15. Cognitive, Disability, and Treatment Outcome Implications of Symptom-Based Phenotyping in Late-Life Depression.
Sudol K; Conway C; Szymkowicz SM; Elson D; Kang H; Taylor WD
Am J Geriatr Psychiatry; 2023 Nov; 31(11):919-931. PubMed ID: 37385899
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study.
Mahajna M; Abu Fanne R; Berkovitch M; Tannous E; Vinker S; Green I; Matok I
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137466
[TBL] [Abstract][Full Text] [Related]
17. Major depressive disorder in hepatitis C: an open-label trial of escitalopram.
Gleason OC; Yates WR; Philipsen MA
Prim Care Companion J Clin Psychiatry; 2005; 7(5):225-30. PubMed ID: 16308578
[TBL] [Abstract][Full Text] [Related]
18. Vortioxetine as a potential alternative for patients with escitalopram-induced jitteriness/anxiety syndrome: A report of three cases.
Arai K; Nonaka M; Shimada S; Nakamura M
PCN Rep; 2023 Dec; 2(4):e158. PubMed ID: 38868737
[TBL] [Abstract][Full Text] [Related]
19. Early Improvement in One Week Predicts the Treatment Response to Escitalopram in Patients with Social Anxiety Disorder: A Preliminary Study.
Oh KS; Shin E; Ha J; Shin D; Shin Y; Lim SW
Clin Psychopharmacol Neurosci; 2016 May; 14(2):161-7. PubMed ID: 27121427
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
